ClinicalTrials.gg

Program

atigotatug

Also written as “BMS-986012” and “BMS-986012 (anti-fucosyl-GM1)”.

Its studies are mostly in Small Cell Lung Carcinoma, led by Bristol-Myers Squibb.

Furthest: phase 2, since Sep 19, 20143 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb30 open or runningphase 2since Sep 19, 2014Sep 19, 2014none ahead
  • Named in Bristol-Myers Squibb’s own pipeline as atigotatug, phase 3, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 19, 2014First study: phase 2 study in Small Cell Lung CarcinomaFirst studyNCT02247349 · 106 enrolled · United States, Australia, Belgium and more
  2. Jun 24, 2016Phase 1 study in Small Cell Lung CarcinomaNCT02815592 · 12 enrolled · Spain
  3. Oct 28, 2016Phase 1 study in Small Cell Lung CarcinomaNCT02949895 · 7 enrolled · Japan

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02949895Small Cell Lung Carcinoma · Japan1CompletedAug 29, 20177
NCT02815592Small Cell Lung Carcinoma · Spain1CompletedDec 15, 201912
NCT02247349Small Cell Lung Carcinoma · United States, Australia, Belgium and more2CompletedDec 21, 2022106

How it is read

Names in the registry

  • “BMS-986012”, 2 entries
  • “BMS-986012 (anti-fucosyl-GM1)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.